The Prostate, Lung, Colon-rectum and Ovary Cancer Screening Trial is designed to determine in screenees aged 60-74 years at entry whether: a. In females and males (1) screening with flexible sigmoidoscopy (60 cm sigmoidoscope) can reduce mortality from colo-rectal cancer; and, (2) screening with chest x-ray can reduce mortality from lung cancer. b.In males (1) screening with digital rectal examination plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer; C.In females (1) screening with pelvic examination plus CA 125 and transvaginal ultrasound can reduce mortality from ovarian cancer; The secondary objectives are: (1) to assess screening variables other than mortality for each of the interventions including sensitivity, specificity, and positive predictive value; (2) to assess incidence, stage, and survival experience of cancer cases and (3) to investigate the mortality predictive value of biologic and or prognostic characterizations of tumor tissue as intermediate endpoints. This contractor will recruit and randomize to screening or control 20,000 subjects in equal gender balance. Screening will be annual for four years, except that sigmoidoscopy will be done only in the initial and last screen. Subjects will be followed for ten years from entry. A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN025512-049
Application #
6344323
Study Section
Project Start
1992-09-30
Project End
2011-09-29
Budget Start
2000-09-30
Budget End
2001-09-30
Support Year
Fiscal Year
2000
Total Cost
$1,594,634
Indirect Cost
Name
Henry Ford Health System
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202
Kang, Xiaozheng; Liu, Hongliang; Onaitis, Mark W et al. (2016) Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls. Carcinogenesis 37:280-289
Pretzel, Shannon M; Andrews, Tara S; Broski, Karen et al. (2015) Participants' Views of Retention Materials Used in the PLCO Cancer Screening Trial. Clin Med Res 13:139-48
Cote, Michele L; Alhajj, Tala; Ruterbusch, Julie J et al. (2015) Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Causes Control 26:287-296
Alford, Sharon Hensley; Rattan, Ramandeep; Buekers, Thomas E et al. (2015) Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Cancer 121:441-7
Brenner, Darren R; Amos, Christopher I; Brhane, Yonathan et al. (2015) Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia. Carcinogenesis 36:1314-26
Tammemägi, Martin C; Berg, Christine D; Riley, Thomas L et al. (2014) Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst 106:dju084
Pinsky, Paul F; Gierada, David S; Hocking, William et al. (2014) National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med 161:627-33
Kvale, Paul A; Johnson, Christine Cole; Tammemägi, Martin et al. (2014) Interval lung cancers not detected on screening chest X-rays: How are they different? Lung Cancer 86:41-6
Wang, Yufei; McKay, James D; Rafnar, Thorunn et al. (2014) Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet 46:736-41
Gierada, David S; Pinsky, Paul; Nath, Hrudaya et al. (2014) Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination. J Natl Cancer Inst 106:

Showing the most recent 10 out of 50 publications